CDKN2D Expression Assay for Senescent Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting senescent cells in neural tissues, particularly in the brain, are limited by low abundance and inconsistent results, making it challenging to identify and treat diseases associated with neurofibrillary tangles and cellular senescence.
Innovation Solution
A method involving the assay of CDKN2D expression in the brain, comparing it to a control, to detect senescent cells and neurofibrillary tangles, and using detectable compounds specific to CDKN2D or p19INK4D for imaging and treatment, including genetic modifying agents and antibodies to inhibit their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional senescence assays (beta-galactosidase activity) are used to detect senescent cells in the brain, then the detection can be performed, but the results are inconsistent and unreliable
Solution Approach 1:
The patent changes the detection parameter from beta-galactosidase activity to CDKN2D expression levels. This parameter change resolves the contradiction by providing a more reliable and consistent marker for senescent cells in the brain, as CDKN2D expression is specifically upregulated in senescent neural cells and can be detected with high precision using immunohistochemistry and Western blotting techniques.
Solution Approach 2:
The patent replaces the biochemical assay mechanism (beta-galactosidase activity measurement) with a molecular biology approach (CDKN2D expression detection). This substitution eliminates the inconsistencies in the original method by directly detecting the molecular signature of senescence rather than relying on indirect enzymatic activity that varies between cell types and conditions.
2Ease of operation
If p16INK4A-immunoreactivity is used as a surrogate marker for senescence, then detection can be performed in accessible tissues, but the low abundance of senescent cells and inability to routinely biopsy brain tissue prevent effective detection
Solution Approach 1:
The patent uses CDKN2D expression as a copy or surrogate marker that better reflects senescent cell presence in the brain. Unlike p16INK4A which has low abundance and requires complex biopsy procedures, CDKN2D can be detected in accessible tissues (blood, CSF) and provides a reliable copy of the senescence state without requiring direct brain tissue biopsy.
Solution Approach 2:
The patent introduces CDKN2D expression as an intermediary marker that bridges the gap between inaccessible brain tissue and accessible peripheral tissues. By detecting CDKN2D in blood or CSF, researchers can indirectly assess senescent cell burden in the brain without requiring invasive biopsies, thus solving the accessibility problem.
3Reliability
If multiple senescence markers are used to improve detection accuracy, then detection reliability may improve, but the complexity of the detection system increases
Solution Approach 1:
The patent extracts and focuses on a single critical marker (CDKN2D) rather than using multiple markers simultaneously. This extraction simplifies the detection system while maintaining high reliability, as CDKN2D alone provides sufficient specificity and sensitivity for detecting senescent cells in the brain, eliminating the need for complex multi-marker panels.
Data Source
AI summary
Provided herein according to some embodiments is a method of detecting senescent cells and/or neurofibrillary tangles in a subject, comprising: assaying for the expression of CDKN2D in the brain of the subject; and comparing the amount of CDKN2D expression to a control, whereby increased CDKN2D expression relative to the control is indicative of the presence of neurofibrillary tangles in the subject. Methods of treating and monitoring a subject so identified are also provided.